WO2001098346A3 - Methods and compositions for the treatment of peripheral artery disease - Google Patents

Methods and compositions for the treatment of peripheral artery disease Download PDF

Info

Publication number
WO2001098346A3
WO2001098346A3 PCT/US2001/019978 US0119978W WO0198346A3 WO 2001098346 A3 WO2001098346 A3 WO 2001098346A3 US 0119978 W US0119978 W US 0119978W WO 0198346 A3 WO0198346 A3 WO 0198346A3
Authority
WO
WIPO (PCT)
Prior art keywords
artery disease
fgf
peripheral artery
compositions
methods
Prior art date
Application number
PCT/US2001/019978
Other languages
French (fr)
Other versions
WO2001098346A2 (en
Inventor
Martha Jo Whitehouse
Original Assignee
Chiron Corp
Martha Jo Whitehouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Martha Jo Whitehouse filed Critical Chiron Corp
Priority to JP2002504301A priority Critical patent/JP2004501164A/en
Priority to AU2001268680A priority patent/AU2001268680A1/en
Priority to EP01946663A priority patent/EP1324766B1/en
Priority to DE60132343T priority patent/DE60132343T2/en
Priority to CA002414020A priority patent/CA2414020A1/en
Publication of WO2001098346A2 publication Critical patent/WO2001098346A2/en
Publication of WO2001098346A3 publication Critical patent/WO2001098346A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.
PCT/US2001/019978 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease WO2001098346A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002504301A JP2004501164A (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease
AU2001268680A AU2001268680A1 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease
EP01946663A EP1324766B1 (en) 2000-06-22 2001-06-22 Fgf-2 for the treatment of peripheral artery disease
DE60132343T DE60132343T2 (en) 2000-06-22 2001-06-22 FGF-2 FOR THE TREATMENT OF DISEASES OF PERIPHERAL ARTERIES
CA002414020A CA2414020A1 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US60/213,504 2000-06-22
US26457201P 2001-01-26 2001-01-26
US60/264,572 2001-01-26
US27654901P 2001-03-16 2001-03-16
US60/276,549 2001-03-16
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease
US09/886,856 2001-06-21

Publications (2)

Publication Number Publication Date
WO2001098346A2 WO2001098346A2 (en) 2001-12-27
WO2001098346A3 true WO2001098346A3 (en) 2003-05-01

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019978 WO2001098346A2 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Country Status (8)

Country Link
US (3) US20020115603A1 (en)
EP (1) EP1324766B1 (en)
JP (1) JP2004501164A (en)
AT (1) ATE383168T1 (en)
AU (1) AU2001268680A1 (en)
CA (1) CA2414020A1 (en)
DE (1) DE60132343T2 (en)
WO (1) WO2001098346A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
CA2480423C (en) 2002-04-08 2012-01-03 The Scripps Research Institute Truncated 24 kda basic fibroblast growth factor
JP4532092B2 (en) * 2003-09-30 2010-08-25 泰彦 田畑 Angiogenic agent
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
EP2522347A1 (en) * 2005-06-29 2012-11-14 Mars Incorporated Flavonols and procyanidins for inducing peripheral blood vessel vasodilation
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
PL2365828T3 (en) 2008-11-07 2015-04-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
JP5734295B2 (en) 2009-08-27 2015-06-17 ザ クリーブランド クリニック ファウンデーション System and method for estimating a site of tissue activity
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
JP5830090B2 (en) 2010-06-14 2015-12-09 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Programming interface for spinal nerve regulation
JP2014513622A (en) 2011-03-29 2014-06-05 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Communication interface for therapeutic stimulus delivery system
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
AU2012294364A1 (en) 2011-08-09 2014-03-20 Boston Scientific Neuromodulation Corporation Remote control for blind clinical trials of electrical stimulation
EP2879757B1 (en) 2012-08-04 2019-06-26 Boston Scientific Neuromodulation Corporation Systems and methods for storing and transferring registration, atlas, and lead information between medical devices
EP2891091B1 (en) 2012-08-28 2018-01-31 Boston Scientific Neuromodulation Corporation Capture and visualization of clinical effects data in relation to a lead and/or locus of stimulation
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US9949738B2 (en) 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US10342551B2 (en) 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10213214B2 (en) 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
EP3204112A1 (en) 2014-10-07 2017-08-16 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
CN107530542B (en) 2015-05-26 2020-10-13 波士顿科学神经调制公司 System for analyzing electrical stimulation and selecting or manipulating activation volume
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
WO2017003946A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US10071249B2 (en) 2015-10-09 2018-09-11 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulation leads
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
AU2017281934B2 (en) 2016-06-24 2019-11-14 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
JP6828149B2 (en) 2016-10-14 2021-02-10 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Systems and methods for closed-loop determination of stimulation parameter settings for electrical stimulation systems
WO2018128949A1 (en) 2017-01-03 2018-07-12 Boston Scientific Neuromodulation Corporation Systems and methods for selecting mri-compatible stimulation parameters
ES2821752T3 (en) 2017-01-10 2021-04-27 Boston Scient Neuromodulation Corp Systems and procedures for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
WO2018187090A1 (en) 2017-04-03 2018-10-11 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
US20200384079A1 (en) * 2017-04-26 2020-12-10 University Of Cincinnati Compositions of Fibroblast Growth Factor LIgands and Methods of Treating Patients Undergoing Ischemia-Reperfusion Therapy
WO2019014224A1 (en) 2017-07-14 2019-01-17 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
WO2019036180A1 (en) 2017-08-15 2019-02-21 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
WO2019210202A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013701A2 (en) * 1998-09-03 2000-03-16 Chiron Corporation Angiogenically effective unit dose of fgf-2 and method of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
WO1996011671A1 (en) 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
JP2000502682A (en) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド Local intravascular delivery of growth factors that promote angiogenesis
SE9802974D0 (en) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013701A2 (en) * 1998-09-03 2000-03-16 Chiron Corporation Angiogenically effective unit dose of fgf-2 and method of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D.F. LAZAROUS ET AL.: "Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 36, no. 4, October 2000 (2000-10-01), pages 1239 - 1244, XP002215812 *
H.T. YANG ET AL.: "Efficacy and specificity of bFGF increased collateral flow in experimental peripheral arterial insufficiency.", AMERICAN JOURNAL OF PHYSIOLOGY: HEART CIRCULATION PHYSIOLOGY, vol. 278, no. 6 part 2, June 2000 (2000-06-01), pages H1966 - H1973, XP002215811 *
J.P. COOKE ET AL.: "Fibroblast growth factor as therapy for critical limb ischemia: a case report.", VASCULAR MEDICINE, vol. 4, no. 2, 1999, London, GB, pages 89 - 91, XP008009072 *
R. BAFFOUR ET AL.: "Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose response effect of basic fibroblast growth factor.", JOURNAL OFVASCULAR SURGERY, vol. 16, no. 2, August 1992 (1992-08-01), pages 181 - 191, XP008008737 *
R.J. LEDERMAN ET AL.: "Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 88, 15 July 2001 (2001-07-15), pages 192 - 195, XP002215813 *

Also Published As

Publication number Publication date
AU2001268680A1 (en) 2002-01-02
WO2001098346A2 (en) 2001-12-27
JP2004501164A (en) 2004-01-15
US20020115603A1 (en) 2002-08-22
CA2414020A1 (en) 2001-12-27
EP1324766A2 (en) 2003-07-09
DE60132343T2 (en) 2008-12-24
US7186407B2 (en) 2007-03-06
DE60132343D1 (en) 2008-02-21
EP1324766B1 (en) 2008-01-09
US7541337B2 (en) 2009-06-02
US20070135348A1 (en) 2007-06-14
ATE383168T1 (en) 2008-01-15
US20040209817A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2001098346A3 (en) Methods and compositions for the treatment of peripheral artery disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
ATE307608T1 (en) COMBINATION OF DOCTAXEL AND RHUMAB HER2 FOR CANCER TREATMENT
ZA942035B (en) Protein formulation
HK1006222A1 (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
IL208184A0 (en) Glp-1, and methods for treating diabetes
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
TW200607509A (en) Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
EP1074258A3 (en) Methods and compositions for treating diseases and conditions of the eye
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
EP1894570A3 (en) Methods and compositions for the treatment of peripheral artery disease
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
RU2130773C1 (en) Method for treating the cases of kaposi sarcoma
RU2140270C1 (en) Method of treatment of patient with kaposi's sarcoma idiopathic type
Zhyl'chuk Increasing the efficacy of treating patients with extensive ovarian cancer by using laferon
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
RU2002122380A (en) A method for the treatment of patients with disseminated forms of prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 504301

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2414020

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946663

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001946663

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001946663

Country of ref document: EP